Encouragingly, according to recent reports in relapsed/refractory B-ALL treated with UCART1928 and in NHL patients treated with ALLO-50129, both products bearing TRAC knock-out generated using TALEN® technology, showed high response rates and allogenic CAR-T cell expansion, supporting the notion that even limited CAR-T cell in vivo persistence is sufficient to produce meaningful responses. This evidence concerns the gene TRAC and non-Hodgkin lymphoma.